[go: up one dir, main page]

EP0610697A1 - Dérivés imidazolique de l'acide phénylacétique prolinamide - Google Patents

Dérivés imidazolique de l'acide phénylacétique prolinamide Download PDF

Info

Publication number
EP0610697A1
EP0610697A1 EP94100845A EP94100845A EP0610697A1 EP 0610697 A1 EP0610697 A1 EP 0610697A1 EP 94100845 A EP94100845 A EP 94100845A EP 94100845 A EP94100845 A EP 94100845A EP 0610697 A1 EP0610697 A1 EP 0610697A1
Authority
EP
European Patent Office
Prior art keywords
carbon atoms
chain
straight
branched alkyl
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP94100845A
Other languages
German (de)
English (en)
Other versions
EP0610697B1 (fr
Inventor
Matthias Dr. Müller-Gliemann
Jürgen Dr. Dressel
Peter Dr. Fey
Rudolf H. Dr. Hanko
Walter Dr. Hübsch
Thomas Dr. Krämer
Ulrich E. Dr. Müller
Martin Dr. Beuck
Stanislav Prof. Dr. Kazda
Stefan Dr. Wohlfeil
Andreas Dr. Knorr
Johannes-Peter Dr. Stasch
Siegfried Dr. Zaiss
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer AG
Original Assignee
Bayer AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer AG filed Critical Bayer AG
Publication of EP0610697A1 publication Critical patent/EP0610697A1/fr
Application granted granted Critical
Publication of EP0610697B1 publication Critical patent/EP0610697B1/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Definitions

  • the invention relates to imidazolyl-substituted phenylacetic acid prolinamides, processes for their preparation and their use in medicaments, in particular as hypotensive and antiatherosclerotic agents.
  • renin a proteolytic enzyme, cleaves the decapeptide angiotensin I in vivo from the angiotensinogen, which in turn is broken down in the lungs, kidneys or other tissues to form the blood pressure-increasing octapeptide angiotensin II.
  • angiotensin II such as vasoconstriction, Na+ retention in the kidney, aldosterone release in the adrenal gland and tone increase in the sympathetic nervous system act synergistically in the sense of an increase in blood pressure.
  • angiotensin II has the property of promoting the growth and proliferation of cells such as cardiac muscle cells and smooth muscle cells, whereby these grow and proliferate in various disease states (e.g. hypertension, atherosclerosis and heart failure).
  • a possible approach to intervene in the renin-angiotensin system is in addition to the inhibition of renin activity, the inhibition of the activity of the angiotensin conversion enzyme (ACE) and the blockade of angiotensin II receptors.
  • RAS renin-angiotensin system
  • the compounds of the general formula (I) according to the invention can also be present in the form of their salts.
  • salts with organic or inorganic bases or acids may be mentioned here.
  • Physiologically acceptable salts are preferred in the context of the present invention.
  • Physiologically acceptable salts of the imidazolyl-substituted phenylacetic acid prolinamides can be salts of the substances according to the invention with mineral acids, carboxylic acids or sulfonic acids.
  • Physiologically acceptable salts can also be metal or ammonium salts of the compounds according to the invention which have a free carboxyl group.
  • metal or ammonium salts of the compounds according to the invention which have a free carboxyl group.
  • Sodium, potassium, magnesium or calcium salts and ammonium salts derived from ammonia, or organic amines such as ethylamine, di- or triethylamine, di- or triethanolamine, dicyclohexylamine, dimethylaminoethanol, arginine, lysine or ethylenediamine.
  • the compounds according to the invention can exist in stereoisomeric forms which either behave like image and mirror image (enantiomers) or do not behave like image and mirror image (diastereomers).
  • the invention relates to both the enantiomers or diastereomers or their respective mixtures. Like the diastereomers, the racemic forms can be separated into the stereoisomerically uniform constituents in a known manner.
  • Customary organic solvents which do not change under the reaction conditions are suitable as solvents for the process.
  • These preferably include ethers such as diethyl ether, dioxane, tetrahydrofuran, glycol dimethyl ether, or hydrocarbons such as benzene, toluene, xylene, hexane, cyclohexane or petroleum fractions or halogenated hydrocarbons such as dichloromethane, trichloromethane, tetrachloromethane, dichlorethylene, trichlorethylene or chlorobenzene, dimethyl, trichloroethylene, dimethylchloride, trichloromethane, dimethylchloride, trichloroethylene, chlorobenzene, trichloroethyl or chlorobenzene , Dimethylformamide, hexamethylphosphoric triamide, acetonitrile, acetone or nitromethane
  • ethers such as diethyl
  • inorganic or organic bases can be used as bases for the process according to the invention.
  • bases preferably include alkali metal hydroxides such as sodium hydroxide or potassium hydroxide, alkaline earth metal hydroxides such as barium hydroxide, alkali metal carbonates such as sodium carbonate, potassium carbonate or cesium carbonate, alkaline earth metal carbonates such as calcium carbonate, or alkali metal or alkaline earth metal alcoholates such as sodium or potassium methoxide, sodium or potassium tert-ethanolate or potassium , or organic amines (trialkyl (C1-C6) amines) such as triethylamine, or heterocycles such as 1,4-diazabicyclo [2.2.2] octane (DABCO), 1,8-diazabicyclo [5.4.0] undec-7-en ( DBU), pyridine, diaminopyridine, methylpiperidine or morpholine. It is also possible to use alkali metals such as sodium or their hydrides such as
  • the base is used in an amount of 0.05 mol to 10 mol, preferably 1 mol to 2 mol, based on 1 mol of the compound of the formula (III).
  • the process according to the invention is generally carried out in a temperature range from -30 ° C. to + 100 ° C., preferably from -10 ° C. to + 60 ° C.
  • the process according to the invention is generally carried out at normal pressure. However, it is also possible to carry out the process under overpressure or under underpressure (e.g. in a range from 0.5 to 5 bar).
  • the usual inorganic bases are suitable as bases for the hydrolysis.
  • bases for the hydrolysis preferably include alkali metal hydroxides or alkaline earth metal hydroxides such as, for example, lithium hydroxide, sodium hydroxide, potassium hydroxide or barium hydroxide, or alkali metal carbonates such as sodium or potassium carbonate or sodium hydrogen carbonate, or alkali metal alcoholates such as sodium methoxide, sodium ethoxide, potassium methoxide, potassium ethoxide or potassium tert-butoxide.
  • Lithium hydroxide, sodium hydroxide or potassium hydroxide is particularly preferably used.
  • Suitable solvents for the saponification are water or the organic solvents customary for hydrolysis. These preferably include alcohols such as methanol, ethanol, propanol, isopropanol or butanol, or ethers such as tetrahydrofuran or dioxane, or dimethylformamide, or dimethyl sulfoxide. Alcohols such as methanol, ethanol, propanol or isopropanol are particularly preferably used. It is also possible to use mixtures of the solvents mentioned.
  • the hydrolysis is preferably carried out with acids such as, for example, trifluoroacetic acid, acetic acid, hydrochloric acid, hydrochloric acid / dioxane, hydrobromic acid, methanesulfonic acid, sulfuric acid or perchloric acid, particularly preferably with trifluoroacetic acid or hydrochloric acid / dioxane.
  • acids such as, for example, trifluoroacetic acid, acetic acid, hydrochloric acid, hydrochloric acid / dioxane, hydrobromic acid, methanesulfonic acid, sulfuric acid or perchloric acid, particularly preferably with trifluoroacetic acid or hydrochloric acid / dioxane.
  • the hydrolysis is generally carried out in a temperature range from 0 ° C. to + 100 ° C., preferably from + 20 ° C. to + 80 ° C.
  • the hydrolysis is carried out at normal pressure. But it is also possible to work under negative pressure or overpressure (e.g. from 0.5 to 5 bar).
  • the base When carrying out the hydrolysis, the base is generally used in an amount of 1 to 3 mol, preferably 1 to 1.5 mol, based on 1 mol of the ester. Molar amounts of the reactants are particularly preferably used.
  • the carboxylates of the compounds according to the invention are formed in the first step as intermediates which can be isolated.
  • the acids according to the invention are obtained by treating the carboxylates with customary inorganic acids. These preferably include acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid or trifluoroacetic acid.
  • customary inorganic acids preferably include acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid or trifluoroacetic acid.
  • acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid or trifluoroacetic acid.
  • amidation and the sulfoamidation are generally carried out in one of the solvents listed above, preferably in tetrahydrofuran or dichloromethane.
  • the amidation or sulfoamidation can optionally proceed from the corresponding acids via the activated stage of the acid halides or mixed anhydrides, which can be prepared from the corresponding acids by reaction with thionyl chloride, phosphorus trichloride, phosphorus pentachloride, phosphorus tribromide or oxalyl chloride or methanesulfonic acid chloride.
  • amidation or sulfoamidation is generally carried out in a temperature range from -50 ° C. to + 80 ° C., preferably from -30 ° C. to + 20 ° C., and normal pressure.
  • suitable bases are preferably triethylamine and / or dimethylaminopyridine, DBU or DABCO.
  • the base is used in an amount of 0.5 mol to 10 mol, preferably 1 mol to 5 mol, based on 1 mol of the compounds of the general formula (V).
  • alkali metal or alkaline earth metal carbonates such as sodium carbonate, potassium carbonate, alkali metal or alkaline earth metal hydroxides such as sodium or potassium hydroxide, or organic bases such as pyridine, triethylamine, N-methylpiperidine, or bicyclic amidines such as 1,5-diazabicyclo [3.4.0] -nonene-5 (DBN) or 1,5-diazabicyclo [3.4.0] undecene-5 (DBU) are used will.
  • Triethylamine is preferred.
  • Suitable dehydrating reagents are carbodiimides such as diisopropylcarbodiimide, dicyclohexylcarbodiimide or N- (3-dimethylaminopropyl) -N'-ethylcarbodiimide hydrochloride or carbonyl compounds such as carbonyldiimidazole or 1,2-oxazolium compounds such as 2-ethyl-5-phenolium-1,2-phenyl-1,2-phenyl-1,2-oxyl 3-sulfonate or propanephosphonic anhydride or isobutylchloroformate or benzotriazolyloxy-tris (dimethylamino) phosphonium hexafluorophosphate or phosphoric acid diphenyl ester amide or methanesulfonic acid chloride, optionally in the presence of bases such as triethylamine or N-ethylmorpholine or N-methylpiperidyl or nodi-cyclohexididine or
  • the acid-binding agents and dehydration reagents are generally used in an amount of 0.5 to 3 mol, preferably 1 to 1.5 mol, based on 1 mol of the corresponding carboxylic acids.
  • the base is used in an amount of from 0.05 mol to 10 mol, preferably from 1 mol to 2 mol, based on 1 mol of the compound of the formula (VII).
  • the process is generally carried out in a temperature range from -30 ° C. to + 100 ° C., preferably from -10 ° C. to + 10 ° C.
  • the process is generally carried out at normal pressure. However, it is also possible to carry out the process under overpressure or under underpressure (e.g. in a range from 0.5 to 5 bar).
  • the compounds according to the invention have a specific A II antagonistic effect, since they competitively inhibit the binding of angiotensin II to the receptors. They suppress the vasoconstrictor and aldosterone secretion-stimulating effects of angiotensin II. In addition, they inhibit the proliferation of smooth muscle cells.
  • They can therefore be used in medicines to treat arterial hypertension and atherosclerosis.
  • they can be used to treat coronary heart diseases, heart failure, brain disorders, ischemic brain diseases, peripheral circulatory disorders, functional disorders of the kidneys and adrenal glands, bronchospastic and vascular diseases of the respiratory tract, sodium retention and edema.
  • Rabbits of both sexes are anesthetized by blows to the neck and bled, or occasionally anesthetized with nembutal (approx. 60 - 80 mg / kg iv) and killed by opening the thorax.
  • the thoracic aorta is removed, free of adhering connective tissue, divided into 1.5 mm wide ring segments and individually under one Initial loading of approx.
  • the contractions are recorded isometrically by Statham UC2 cells via bridge amplifiers (ifd Mülheim or DSM Aalen) and digitized and evaluated using an A / D converter (System 570, Keithley Kunststoff).
  • the agonist dose response curves (DWK) are carried out every hour. With each DWK, 3 or 4 individual concentrations are applied to the baths every 4 minutes. After the end of the DWK and the subsequent wash-out cycles (16 times approx. 5 sec / min each with the above-mentioned nutrient solution), there is a 28-minute rest or incubation phase, during which the contractions usually return to the initial value.
  • the level of the 3rd DWK is normally used as a reference value for evaluating the test substance to be examined in further runs, which is applied to the subsequent DWKs in increasing doses at the beginning of the incubation period in the baths.
  • Each aortic ring is stimulated with the same agonist all day.
  • the effect at the 3rd submaximal agonist concentration is taken as a basis.
  • the compounds according to the invention inhibit the contraction of the isolated rabbit aorta induced by angiotensin II in a dose-dependent manner.
  • the contraction induced by potassium depolarization or other agonists was not inhibited or only weakly inhibited in high concentrations.
  • Male Wistar rats (Moellegaard, Copenhagen, Denmark) with a body weight of 300 - 350 g are anesthetized with thiopental (100 mg / kg i.p.).
  • a catheter for blood pressure measurement is inserted into the femoral artery and a catheter for angiotensin II infusion and a catheter for substance administration are inserted into the femoral veins.
  • the ganglion blocker pentolinium 5 mg / kg i.v.
  • the angiotensin II infusion (0.3 ⁇ g / kg / min) is started.
  • the test substances are administered orally either intravenously or as a suspension or solution in 0.5% tylose.
  • the oral antihypertensive activity of the compounds according to the invention was tested on awake rats with surgically induced unilateral renal artery stenosis.
  • the right renal artery was narrowed with a silver clip of 0.18 mm inside diameter.
  • the plasma arena activity is increased in the first six weeks after the procedure.
  • the arterial blood pressure of these animals was measured without blood at defined time intervals after administration of substance with the "tail cuff".
  • the ones to be checked Substances were suspended in a tylose suspension intragastral ("oral") by gavage in various doses.
  • the compounds according to the invention lower the arterial blood pressure of the high-pressure rats in a clinically relevant dose.
  • the compounds according to the invention inhibit the specific binding of radioactive angiotensin II in a concentration-dependent manner.
  • Bovine adrenal cortex (NNR), freshly removed and carefully removed from capsule capsule, is crushed in sucrose solution (0.32 M) using an Ultra-Turrax (Janke & Kunkel, Staufen iB) to form coarse membrane homogenate and partially purified to membrane fractions in two centrifugation steps.
  • the studies on receptor binding are carried out on partially purified membrane fractions of bovine NNR with radioactive angiotensin II in an assay volume of 0.25 ml, which in detail contains the partially purified membranes (50 - 80 ⁇ g), 3 H-angiotensin II (3- 5 nM), test buffer solution (50 mM Tris, pH 7.2), 5 mM MgCl2 and the substances to be investigated.
  • smooth muscle cells are used, which are obtained from the aorta of rats by the media explant technique [R. Ross, J. Cell. Biol. 50 , 172, 1971].
  • the cells are sown in suitable culture dishes, usually 96-well plates, and for 2-3 days in medium 199 with 7.5% FCS and 7.5% NCS, 2 mM L-glutamine and 15 mM HEPES, pH 7.4 cultured in 5% CO2 at 37 ° C.
  • the cells are then synchronized by serum withdrawal for 2-3 days and then stimulated to grow with serum or other factors.
  • test compounds are added.
  • the new active compounds can be converted in a known manner into the customary formulations, such as tablets, dragées, pills, granules, aerosols, syrups, emulsions, suspensions and solutions, using inert, non-toxic, pharmaceutically suitable excipients or solvents.
  • the therapeutically active compound should in each case be present in a concentration of about 0.5 to 90% by weight of the total mixture, i.e. in amounts sufficient to achieve the dosage range indicated.
  • the formulations are prepared, for example, by stretching the active ingredients with solvents and / or carriers, optionally using emulsifiers and / or dispersants, e.g. if water is used as the diluent, organic solvents can optionally be used as auxiliary solvents.
  • the application is carried out in the usual way, preferably orally or parenterally, in particular perlingually or intravenously.
  • solutions of the active ingredient can be used using suitable liquid carrier materials.
  • 0.11 g (0.22 mmol) of the compound from Example 4 in 5 ml of tetrahydrofuran are mixed with 0.05 ml (0.44 mmol) of triethylamine at room temperature, and the mixture is cooled to -30 ° C. with stirring.
  • 0.03 g (0.24 mmol) of methanesulfonic acid chloride is added and, after stirring for 90 minutes, a solution of 0.03 g (0.24 mmol) of L-phenylglycinol in 5 ml of tetrahydrofuran is added dropwise, and the mixture is stirred at -30 ° for 1 hour C. and allowed to warm to room temperature overnight.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Epoxy Resins (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP94100845A 1993-02-03 1994-01-21 Dérivés imidazolique de l'acide phénylacétique prolinamide Expired - Lifetime EP0610697B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE4302957A DE4302957A1 (de) 1993-02-03 1993-02-03 Imidazolyl-substituierte Phenylessigsäureprolinamide
DE4302957 1993-02-03

Publications (2)

Publication Number Publication Date
EP0610697A1 true EP0610697A1 (fr) 1994-08-17
EP0610697B1 EP0610697B1 (fr) 1997-03-12

Family

ID=6479487

Family Applications (1)

Application Number Title Priority Date Filing Date
EP94100845A Expired - Lifetime EP0610697B1 (fr) 1993-02-03 1994-01-21 Dérivés imidazolique de l'acide phénylacétique prolinamide

Country Status (8)

Country Link
US (1) US5459156A (fr)
EP (1) EP0610697B1 (fr)
JP (1) JPH06271573A (fr)
AT (1) ATE150018T1 (fr)
DE (2) DE4302957A1 (fr)
DK (1) DK0610697T3 (fr)
ES (1) ES2099494T3 (fr)
GR (1) GR3023194T3 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6774236B1 (en) * 1996-04-04 2004-08-10 Bayer Aktiengesellschaft Process for the preparation of enantiomerically pure cycloalkano-indol -and azaindol -and pyrimido [1,2A]indolcarbocyclic acids and their activated derivatives
US6329342B1 (en) 1997-08-19 2001-12-11 Eli Lilly And Company Treatment of congestive heart failure with growth hormone secretagogues
US6639076B1 (en) * 1998-08-18 2003-10-28 Eli Lilly And Company Growth hormone secretagogues
US6828331B1 (en) 1999-02-19 2004-12-07 Eli Lilly And Company Growth hormone secretagogues
US7125840B2 (en) * 2001-10-09 2006-10-24 Eli Lilly And Company Substituted dipeptides as growth hormone secretagogues
WO2003087069A2 (fr) * 2002-04-09 2003-10-23 Eli Lilly And Company Secretagogues d'hormone de croissance
US20060167268A1 (en) * 2002-04-09 2006-07-27 Eli Lilly And Company, Patent Division, Growth hormone secretagogues
WO2015039758A1 (fr) * 2013-09-19 2015-03-26 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Ligands sélectifs de la fkbp51 destinés au traitement de troubles psychiatriques
EP3245198B1 (fr) * 2015-01-13 2020-03-11 Novartis AG Dérivés de pyrrolidine utilisés en tant qu'antagonistes de l' angiotensin ii type 2

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0010347A1 (fr) * 1978-09-05 1980-04-30 American Cyanamid Company Omega-aroyl(propionyl ou butyryl)-L-prolines substituées, compositions pharmaceutiques les contenant et procédés pour leur préparation
WO1991012002A1 (fr) * 1990-02-13 1991-08-22 Merck & Co., Inc. Agents antagonistes de l'angiotensine ii a base d'imidazoles dans lesquels est incorpore un element de benzyle substitue
EP0513533A2 (fr) * 1991-04-26 1992-11-19 Bayer Ag Dérivés substitués hétérocycliques de l'acide phenyl acétique, procédé pour leur fabrication et leur application comme médicaments
EP0560163A1 (fr) * 1992-03-13 1993-09-15 Bayer Ag Dérivés substitués imidazolylméthyl de l'amide phényl acétique, procédé pour leur fabrication et leur application comme médicaments
EP0573271A1 (fr) * 1992-06-03 1993-12-08 Eli Lilly And Company Antagonistes de l'angiotensine II

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5138069A (en) * 1986-07-11 1992-08-11 E. I. Du Pont De Nemours And Company Angiotensin II receptor blocking imidazoles

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0010347A1 (fr) * 1978-09-05 1980-04-30 American Cyanamid Company Omega-aroyl(propionyl ou butyryl)-L-prolines substituées, compositions pharmaceutiques les contenant et procédés pour leur préparation
WO1991012002A1 (fr) * 1990-02-13 1991-08-22 Merck & Co., Inc. Agents antagonistes de l'angiotensine ii a base d'imidazoles dans lesquels est incorpore un element de benzyle substitue
EP0513533A2 (fr) * 1991-04-26 1992-11-19 Bayer Ag Dérivés substitués hétérocycliques de l'acide phenyl acétique, procédé pour leur fabrication et leur application comme médicaments
EP0560163A1 (fr) * 1992-03-13 1993-09-15 Bayer Ag Dérivés substitués imidazolylméthyl de l'amide phényl acétique, procédé pour leur fabrication et leur application comme médicaments
EP0573271A1 (fr) * 1992-06-03 1993-12-08 Eli Lilly And Company Antagonistes de l'angiotensine II

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
J.V.DUNCIA ET AL: "The discovery of potent nonpeptide angiotensin II receptor antagonists: A new class of potent antihypertensives.", J. MED. CHEM., vol. 33, 1990, pages 1312 - 1329, XP002230208, DOI: doi:10.1021/jm00167a007 *

Also Published As

Publication number Publication date
EP0610697B1 (fr) 1997-03-12
JPH06271573A (ja) 1994-09-27
ES2099494T3 (es) 1997-05-16
DE4302957A1 (de) 1994-08-04
ATE150018T1 (de) 1997-03-15
DK0610697T3 (da) 1997-09-15
DE59401990D1 (de) 1997-04-17
US5459156A (en) 1995-10-17
GR3023194T3 (en) 1997-07-30

Similar Documents

Publication Publication Date Title
EP0542059B1 (fr) Biphénylpyridinones substitués comme antagonistes de l'angiotensine II
EP0624583B1 (fr) Pyridylméthylpyridones substituées comme antagonistes d'angiotensine II
EP0611767B1 (fr) Dérivés d'acides carboxyliques de cyclohexane phényle substitués par hétérocycles
DE4206045A1 (de) Sulfonylbenzyl substituierte pyridone
EP0569795B1 (fr) Benzo- et pyridopyridones substitués par sulfonylebenzyle
EP0560163A1 (fr) Dérivés substitués imidazolylméthyl de l'amide phényl acétique, procédé pour leur fabrication et leur application comme médicaments
EP0539713A1 (fr) Dérivés substitués d'acide imidazolylpropénique comme inhibiteurs d'angiotensine II
EP0535465A1 (fr) Dérivés cycliques substitués d'acide imidazolylpropenique comme antagonistes d'angiotensin II
EP0610698B1 (fr) Imidazo(4,5-b)pyridines et benzinimidazoles substitués comme angiotensin II antagonistes
EP0569794A1 (fr) Pyridones substitué par biphényleméthyle utiles comme inhibiteurs des récepteurs de l'angiotensin II
EP0610697B1 (fr) Dérivés imidazolique de l'acide phénylacétique prolinamide
EP0560162A1 (fr) Dérivés substitués imidazolylméthyl de l'amide phényl acétique, procédé pour leur fabrication et leur application comme médicaments
EP0535463A1 (fr) Dérivés d'acide imidazolylpropénique comme antagonistes d'angiotensin II
EP0617035B1 (fr) Dérivés de l'acide phényle-cyclohexane-carboxylique substitués par des groupes hétéro-tricycliques
EP0608709A1 (fr) Dérives d'acide 2-oxe-quinoléin-1-yl-méthyl-phényl acétique comme angiotensin II antagonistes
EP0578002A1 (fr) Dérivés d'acide phénylpropionique et cinnamique substitués par imidazole
EP0630896A1 (fr) Dérivés substituées de mono- et bipyridylméthyl comme antagonistes de l'angiotensine II
EP0622358A1 (fr) Phénylglycinamides d'acides 4-imidazolylméthyl-phényl-acétiques et leur utilisation contre l'hypertension et l'athérosclérose
EP0581003B1 (fr) Dérivés du cyclohexane substitués par imidazole
EP0565986A2 (fr) Dérivés de propénoyl-imidazole, leur préparation et leur utilisation comme médicaments avec une activité angiotensine II antagonistique
EP0594022A1 (fr) Pyridone biphényles alkoxyméthyle substitués comme antagonistes de l'angiotensine II
EP0557842A2 (fr) Dérivés d'acide sulphonylbenzyl-imidazolylpropénique substitués
EP0563705A2 (fr) Dérivés d'acide cycloalkyl- et hétérocyclyl-imidazolylpropénique substitués
EP0643060A2 (fr) Benzimadazoles substituées par sulfonylbenzyle, procédé pour leur préparation, et leur application en tant que médicaments
EP0626382A1 (fr) 2,4-Imidazolidinediones substituées comme agents antihypertensifs et antiathérosclérotiques

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

17P Request for examination filed

Effective date: 19950111

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

17Q First examination report despatched

Effective date: 19960325

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

REF Corresponds to:

Ref document number: 150018

Country of ref document: AT

Date of ref document: 19970315

Kind code of ref document: T

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: E. BLUM & CO. PATENTANWAELTE

Ref country code: CH

Ref legal event code: EP

GBT Gb: translation of ep patent filed (gb section 77(6)(a)/1977)

Effective date: 19970318

REF Corresponds to:

Ref document number: 59401990

Country of ref document: DE

Date of ref document: 19970417

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

Free format text: 72692

ITF It: translation for a ep patent filed
REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2099494

Country of ref document: ES

Kind code of ref document: T3

ET Fr: translation filed
REG Reference to a national code

Ref country code: GR

Ref legal event code: FG4A

Free format text: 3023194

REG Reference to a national code

Ref country code: PT

Ref legal event code: SC4A

Free format text: AVAILABILITY OF NATIONAL TRANSLATION

Effective date: 19970415

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 19971212

Year of fee payment: 5

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IE

Payment date: 19971216

Year of fee payment: 5

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SE

Payment date: 19971219

Year of fee payment: 5

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GR

Payment date: 19971223

Year of fee payment: 5

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 19971224

Year of fee payment: 5

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: LU

Payment date: 19980106

Year of fee payment: 5

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 19980112

Year of fee payment: 5

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: MC

Payment date: 19980115

Year of fee payment: 5

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: AT

Payment date: 19980120

Year of fee payment: 5

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 19980126

Year of fee payment: 5

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DK

Payment date: 19980128

Year of fee payment: 5

Ref country code: BE

Payment date: 19980128

Year of fee payment: 5

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 19980129

Year of fee payment: 5

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 19980130

Year of fee payment: 5

26N No opposition filed
PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: PT

Payment date: 19980721

Year of fee payment: 5

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 19990121

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 19990121

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 19990121

Ref country code: AT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 19990121

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 19990122

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 19990122

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 19990131

Ref country code: GR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 19990131

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 19990131

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 19990131

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 19990202

BERE Be: lapsed

Owner name: BAYER A.G.

Effective date: 19990131

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 19990731

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 19990731

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 19990801

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 19990121

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 19990930

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 19991103

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

REG Reference to a national code

Ref country code: PT

Ref legal event code: MM4A

Free format text: LAPSE DUE TO NON-PAYMENT OF FEES

Effective date: 19990731

REG Reference to a national code

Ref country code: DK

Ref legal event code: EBP

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20010503

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES;WARNING: LAPSES OF ITALIAN PATENTS WITH EFFECTIVE DATE BEFORE 2007 MAY HAVE OCCURRED AT ANY TIME BEFORE 2007. THE CORRECT EFFECTIVE DATE MAY BE DIFFERENT FROM THE ONE RECORDED.

Effective date: 20050121